Topics

Another blow to Alzheimer’s field as two drugs fail in study of early-onset disease

11:31 EST 11 Feb 2020 | MedCity News

Dementia or brain damage and injury as a mental health and neurology medical symbol with a thinking human organ made of crumpled paper torn in pieces as a creative concept for alzheimer disease.

Lilly and Roche said that the Phase II/III DIAN-TU trial of their amyloid beta-targeting drugs – gantenerumab and solanezumab – failed to meet its primary endpoint in patients genetically predisposed to early-onset Alzheimer’s disease.

Original Article: Another blow to Alzheimer’s field as two drugs fail in study of early-onset disease

NEXT ARTICLE

More From BioPortfolio on "Another blow to Alzheimer’s field as two drugs fail in study of early-onset disease"

Quick Search

Relevant Topics

Lilly
Eli Lilly and Company was founded in 1876, and is now the 9th largest pharmaceutical company based an annual sales which were just under $20bn in 2009. Orginally from the USA, Lilly now operates in over 50 countries with just under 40,000 employees. Appr...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...